- Title
- Combined vaginal progesterone and cervical cerclage in the prevention of preterm birth: a systematic review and meta-analysis.
- Creator
- Aubin, Anne -Marie; McAuliffe, Liam; Williams, Kimberley; Issah, Ashad; Diacci, Rosanna; McAuliffe, Jack E.; Sabdia, Salma; Phung, Jason; Wang, Carol A.; Pennell, Craig E.
- Relation
- American journal of obstetrics & gynecology MFM Vol. 5, Issue 8, no. 101024
- Publisher Link
- http://dx.doi.org/10.1016/j.ajogmf.2023.101024
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2023
- Description
- Objective: Vaginal progesterone and cervical cerclage are both effective interventions for reducing preterm birth. It is currently unclear whether combined therapy offers superior effectiveness than single therapy. This study aimed to determine the efficacy of combining cervical cerclage and vaginal progesterone in the prevention of preterm birth. Data sources: We searched Medline (Ovid), EMBASE (Ovid), PsycINFO (Ovid), CINAHL (EBSCOhost), Cochrane Library (Wiley), and Scopus (from their inception to 2020). Study eligibility criteria: The review accepted randomized and pseudorandomized control trials, nonrandomized experimental control trials, and cohort studies. High risk patients (shortened cervical length <25mm or previous preterm birth) who were assigned cervical cerclage, vaginal progesterone, or both for the prevention of preterm birth were included. Only singleton pregnancies were assessed. Methods: The primary outcome was birth <37 weeks. Secondary outcomes included birth <28 weeks, <32 weeks and <34 weeks, gestational age at delivery, days between intervention and delivery, preterm premature rupture of membranes, cesarean delivery, neonatal mortality, neonatal intensive care unit admission, intubation, and birthweight. Following title and full-text screening, 11 studies were included in the final analysis. Risk of bias was assessed using the Cochrane Collaboration tool for assessing the risk of bias (ROBINS-I and RoB-2). Quality of evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) tool. Results: Combined therapy was associated with lower risk of preterm birth at <37 weeks than cerclage alone (risk ratio, 0.51; 95% confidence interval, 0.37-0.79) or progesterone alone (risk ratio, 0.75; 95% confidence interval, 0.58-0.96). Compared with cerclage only, combined therapy was associated with preterm birth at <34 weeks, <32 weeks, or <28 weeks, decreased neonatal mortality, increased birthweight, increased gestational age, and a longer interval between intervention and delivery. Compared with progesterone alone, combined therapy was associated with preterm birth at <32 weeks, <28 weeks, decreased neonatal mortality, increased birthweight, and increased gestational age. There were no differences in any other secondary outcomes. Conclusion: Combined treatment of cervical cerclage and vaginal progesterone could potentially result in a greater reduction in preterm birth than in single therapy. Further, well-conducted and adequately powered randomized controlled trials are needed to assess these promising findings.
- Subject
- cervical cerlage; preterm birth; progestins; vaginal progesterone; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1485512
- Identifier
- uon:51617
- Identifier
- ISSN:2589-9333
- Language
- eng
- Reviewed
- Hits: 2524
- Visitors: 2521
- Downloads: 0
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format |
|---|